Development and Characterization of Vesicular Drug Delivery Systems for Melanoma Treatment
Project no. 23840 · Status: Kapanmış · 2022
Summary
<p>Melanoma is a skin disease characterized by lesions on the skin and can result in death. Today, chemotherapeutics are frequently used in the treatment of skin cancer, but their use may be limited due to serious side effects, inability to target the drug to the desired area in the desired amount, and the desired efficiency of the treatment may not be achieved.</p><p>The use of immunomodulators in skin cancer treatment is a good alternative to avoid the unwanted effects of chemotherapeutics. In addition, topical application of the drug is very effective in terms of reaching the desired area.</p><p>Polyphenolic compounds (PBs) are generally derived from plants and have many effects in the literature such as anticancer, antioxidant, antithrombolic, skin protection from damage caused by ionizing radiation and antiallergic. Studies have reported that the use of these compounds in the topical treatment of skin cancer is beneficial. However, due to the chemical instability of PBs, their use with conventional drug delivery systems is limited.</p><p>To overcome this problem, liposomes containing PBs were developed in this project. This is expected to increase the stability of PB. In this context, a liposome formulation that has never been studied before has been developed with the combination of selected lipids and active ingredients. This formulation is aimed to kill cancer cells while causing less damage to healthy cells and an alternative treatment approach to chemotherapeutics in melanoma treatment has been developed. </p><p>With this project, a formulation in which PBs can be used in the treatment of skin cancer was developed and characterization, release and cell culture studies of this formulation were carried out. This project was supported by Ege University BAP Unit with PhD thesis project number 23840.</p><p> </p>